Sabina Mugusi
Sabina Mugusi
Muhimbili University of Health and Allied Sciences
Verified email at muhas.ac.tz
Title
Cited by
Cited by
Year
Long‐term efavirenz autoinduction and its effect on plasma exposure in HIV patients
E Ngaimisi, S Mugusi, OM Minzi, P Sasi, KD Riedel, A Suda, N Ueda, ...
Clinical Pharmacology & Therapeutics 88 (5), 676-684, 2010
1142010
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa …
E Ngaimisi, A Habtewold, O Minzi, E Makonnen, S Mugusi, W Amogne, ...
PloS one 8 (7), e67946, 2013
1102013
Effect of Rifampicin and CYP2B6 Genotype on Long‐Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis
E Ngaimisi, S Mugusi, O Minzi, P Sasi, KD Riedel, A Suda, N Ueda, ...
Clinical Pharmacology & Therapeutics 90 (3), 406-413, 2011
792011
Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania
S Mugusi, E Ngaimisi, M Janabi, O Minzi, M Bakari, KD Riedel, ...
PloS one 7 (7), e40180, 2012
682012
Enhancing adherence to antiretroviral therapy at the HIV clinic in resource constrained countries; the Tanzanian experience
F Mugusi, S Mugusi, M Bakari, B Hejdemann, R Josiah, M Janabi, ...
Tropical Medicine & International Health 14 (10), 1226-1232, 2009
502009
β-defensin genomic copy number is associated with HIV load and immune reconstitution in sub-saharan Africans
RJ Hardwick, W Amogne, S Mugusi, G Yimer, E Ngaimisi, A Habtewold, ...
The Journal of infectious diseases 206 (7), 1012-1019, 2012
462012
Frequency of the SLCO1B1 388A> G and the 521T> C polymorphism in Tanzania genotyped by a new LightCycler®-based method
E Aklillu, S Mugusi, E Ngaimisi, MM Hoffmann, S König, V Ziesenitz, ...
European journal of clinical pharmacology 67 (11), 1139-1145, 2011
342011
CCL3L1 copy number, HIV load, and immune reconstitution in sub-Saharan Africans
E Aklillu, L Odenthal-Hesse, J Bowdrey, A Habtewold, E Ngaimisi, ...
BMC infectious diseases 13 (1), 1-10, 2013
312013
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment
E Ngaimisi, O Minzi, S Mugusi, P Sasi, KD Riedel, A Suda, N Ueda, ...
Journal of Antimicrobial Chemotherapy 69 (12), 3311-3319, 2014
202014
Effect of improved access to antiretroviral therapy on clinical characteristics of patients enrolled in the HIV care and treatment clinic, at Muhimbili National Hospital (MNH …
SF Mugusi, JC Mwita, JM Francis, S Aboud, M Bakari, EA Aris, AB Swai, ...
BMC Public Health 10 (1), 1-7, 2010
202010
SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine
E Aklillu, A Habtewold, E Ngaimisi, G Yimer, S Mugusi, W Amogne, ...
Omics: a journal of integrative biology 20 (9), 538-545, 2016
192016
Copy number variation of Fc gamma receptor genes in HIV-infected and HIV-tuberculosis co-infected individuals in sub-Saharan Africa
LR Machado, J Bowdrey, E Ngaimisi, A Habtewold, O Minzi, E Makonnen, ...
PloS one 8 (11), e78165, 2013
192013
Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania.
SF Mugusi, E Ngaimisi, MY Janabi, FM Mugusi, O Minzi, PG Sasi, ...
Antiviral therapy 17 (2), 265-74, 2012
182012
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second …
J Svärd, S Mugusi, D Mloka, U Neogi, G Meini, F Mugusi, F Incardona, ...
PloS one 12 (6), e0178942, 2017
122017
Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
S Mugusi, E Ngaimisi, M Janabi, F Mugusi, O Minzi, E Aris, M Bakari, ...
European journal of clinical pharmacology 74 (11), 1405-1415, 2018
72018
Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/tuberculosis patients with the same CYP2B6* 6 genotype
EN Kitabi, OMS Minzi, S Mugusi, P Sasi, M Janabi, F Mugusi, L Bertilsson, ...
Scientific reports 8 (1), 1-12, 2018
42018
Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort …
S Mugusi, A Habtewold, E Ngaimisi, W Amogne, G Yimer, O Minzi, ...
Frontiers in pharmacology 11, 26, 2020
12020
Adherence to combination antiretroviral therapy among orphaned children in Dar es Salaam, Tanzania
SF Mugusi, N Mopei, O Minzi
Southern African journal of HIV medicine 20 (1), 1-8, 2019
12019
Optimization of HIV and tuberculosis co-treatment in Tanzania: drug-drug interactions and clinical outcomes
S Mugusi
Inst för klinisk forskning och utbildning, Södersjukhuset/Dept of Clinical …, 2013
12013
A Comparison of Patients on First Line and Second Line Antiretroviral Therapy in Dar es Salaam, Tanzania
GA Shayo, FB Seleki, SF Mugusi, FM Mugusi
Tanzania Medical Journal 31 (4), 77-92, 2020
2020
The system can't perform the operation now. Try again later.
Articles 1–20